Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06572423 · ClinicalTrials.gov registry record · NA

Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy for Palliative Head and Neck Cancer Treatment (PULS-Pal)

A NA study of Head and Neck Carcinoma and Metastatic Head and Neck Carcinoma, sponsored by Jonsson Comprehensive Cancer Center.

Recruiting
Registry status
NA
Development phase
43
Enrollment target
1
Study location

NCT06572423: Recruiting NA study of Head and Neck Carcinoma and Metastatic Head and Neck Carcinoma, sponsored by Jonsson Comprehensive Cancer Center.

NCT06572423 is a NA study of Head and Neck Carcinoma and Metastatic Head and Neck Carcinoma that is actively recruiting participants, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 43 participants, below the 412-participant average among 30 other Head and Neck Carcinoma trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06572423, a NA study of Head and Neck Carcinoma and Metastatic Head and Neck Carcinoma, is actively recruiting participants, sponsored by Jonsson Comprehensive Cancer Center.

RECRUITING
Registry status
NA
Development phase
43 participants
Enrollment target
1
Study location

Study Summary

This trial tests how well personalized ultra fractionated stereotactic adaptive radiotherapy (PULSAR) works together with HyperArc© radiation treatment planning technology for palliative (holistic pain and symptom control) tumor control in patients with primary or recurrent, localized or metastatic head and neck cancer (HNC) who are ineligible for or decline standard of care treatment. Researchers want to evaluate if using HyperArc and PULSAR together will deliver higher, possibly more effective doses, resulting in better tumor control with the same or fewer side effects than smaller routine doses. PULSAR is a radiation therapy regimen that uses a limited number of fairly large dose pulses while adjusting to specific anatomic and/or biological changes which may occur during the course of the treatment. HyperArc radiation treatment planning technology is a tool that allows for target dose escalation to tumor tissue while maintaining minimal head and neck organs-at-risk doses compared to other radiation treatment planning software. Undergoing PULSAR and HyperArc technology together may be a safe and effective palliative treatment option for patients with HNC.

Primary Outcome

Progression of the treated tumor target will be determined clinically and/or radiographically as applicable. Time to progression of the treated tumor target will be reported descriptively for each patient. One-year treated tumor target progression free survival will be estimated by the Kaplan-Meier method, descriptively (mean, standard deviation, median, first and third quartiles, minimum, maximum), and will consider the competing risk of death.

Conditions Studied

Head and Neck Carcinoma Metastatic Head and Neck Carcinoma Recurrent Head and Neck Carcinoma Localized Head and Neck Carcinoma

Interventions

  • PROCEDURE Computed Tomography
  • PROCEDURE Magnetic Resonance Imaging
  • PROCEDURE Positron Emission Tomography
  • PROCEDURE Personalized ultrafractionated stereotactic adaptive radiotherapy
  • RADIATION Volume Modulated Arc Therapy

Study Locations (1)

California

  • University of California at Los Angeles - Los Angeles

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2024-10-25
Est. Completion 2029-12-16
Phase NA
Jonsson Comprehensive Cancer Center

321 total trials

What NCT06572423 shows while recruiting

NCT06572423 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 412-participant average among 30 other Head and Neck Carcinoma trials with a reported enrollment target (90% lower).

The record links to 4 conditions, with Head and Neck Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.

NCT06572423 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06572423 about?

NCT06572423 is a clinical study titled "Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy for Palliative Head and Neck Cancer Treatment (PULS-Pal)". This trial tests how well personalized ultra fractionated stereotactic adaptive radiotherapy (PULSAR) works together with HyperArc© radiation treatment planning technology for palliative (holistic pain and symptom control) tumor control in patients with primary or recurrent, localized or metastatic ...

What is the current status of trial NCT06572423?

This trial is currently recruiting. It is a NA study. The enrollment target is 43 participants. The study started on 2024-10-25. Estimated completion is 2029-12-16.

What conditions does trial NCT06572423 study?

This clinical trial studies the following conditions: Head and Neck Carcinoma, Metastatic Head and Neck Carcinoma, Recurrent Head and Neck Carcinoma, Localized Head and Neck Carcinoma.

What interventions are being tested in trial NCT06572423?

The interventions under investigation include: Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Positron Emission Tomography (PROCEDURE), Personalized ultrafractionated stereotactic adaptive radiotherapy (PROCEDURE), Volume Modulated Arc Therapy (RADIATION).

Who is sponsoring clinical trial NCT06572423?

This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06572423 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06572423's enrollment target sits among peer trials

43 17th of 30 higher than 14 of 30 other Head and Neck Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Head and Neck Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03726359 · 43 participants · Phase 1

    Phase I Study of Fractionated Stereotactic Radiation Therapy

  • NCT03850418 · 43 participants · Phase 2

    Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

  • NCT04144023 · 43 participants · Phase 1

    A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

  • NCT04176718 · 43 participants · Phase 2

    Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06572423

Source: ClinicalTrials.gov NCT06572423, the US trial registry maintained by the National Library of Medicine. NCT06572423 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.